Back to top

Tale of the Tape

Catalyst Pharmaceutical Partners, Inc.’s (CPRX - Analyst Report) share price has entered into oversold territory with an RSI value of 25.81. The Zacks Consensus Estimate on Catalyst Pharmaceutical Partners, Inc.’s earnings for the full year period has loss of 0.01 cents over the past two months to $-0.25 per share. Currently, Catalyst Pharmaceutical Partners, Inc. is a Zacks #1 Rank (“Strong Buy”), suggesting that now might be a good time to get in on (CPRX - Analyst Report) after its recent drop.